A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
Status:
Completed
Trial end date:
2017-02-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that CNTO 328 when administered in combination
with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic
response (complete response or partial response) among patients with Multicentric Castleman's
Disease.